Botox® and Azzalure are both compounds of botulinum toxin type A, a neurotoxin produced by the Clostridium botulinum.
Botox was approved by the Food and Drug Administration (FDA) for the cosmetic treatment of wrinkles and frown lines in 2002; Dysport was approved for the same use in 2009.
As injectable treatments for wrinkles and frown lines, Botox and Azzalure work similarly: they both contain very small doses of botulinum toxin, which inhibits the stimulation of nerves, with the effect of relaxing the muscles that cause facial wrinkles. Azzalure spreads a bit farther from the injection point than Botox. This is an advantage, as fewer injections are required in large areas (such as the forehead), with less potential discomfort for the patient.
In the treatment of lateral orbital rhytids (commonly known as “crow’s feet”), Azzalure is believed to produce better results than Botox on patients’ appearance when facial muscles are contracted; however, the difference is hardly noticeable when facial muscles are at rest.
However, with that being said, there have been numerous studies performed to assess the differences between the different preparations, and there is the wealth of anecdotal evidence collected as expert opinion from doctors who have performed thousands of treatments. The duration of effect has been studied, the side effect profile, the spread, the diffusion, patient and practitioner satisfaction. So far no signifiant difference in the overall effects between the two has been identified. In short, for the patient, there is no significant clinical difference between the formulations, it is simply up to which formulation your consultant feels is best suited to you.
We recommend booking an appointment at Cadogan Clinic to see which one is right for you.